Background and Aims: To enhance screening and diagnosis in those at-risk of hepatitis C virus (HCV), efficient and improved sampling and testing is required. We investigated the performance of point-of-care (POC) tests and dried blood spots (DBS) for HCV antibody and HCV RNA quantification in individuals at higher risk for HCV (people who use and inject drugs, sex workers and men who have sex with men) in seven South African cities. Methods: Samples were screened on the OraQuick HCV POC test (471 whole blood and 218 oral fluid); 218 whole blood and DBS paired samples were evaluated on the ARCHITECT HCV antibody (Abbott) and HCV viral load (COBAS Ampliprep/COBAS TaqMan version 2) assays. For HCV RNA quantification, 107 dB were analy...
International audienceBackground: Although novel hepatitis C virus (HCV) RNA point‐of‐care technolog...
The relative contribution of serologic screening and nucleic acid testing (NAT) to prevent hepatitis...
Background Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage over antibody testi...
International audienceIntroduction: A lack of access to hepatitis C virus (HCV) diagnostics is a sig...
Background: Rapid tests for the detection of antibodies to hepatitis C virus (anti-HCV) can facilita...
Background: Testing for hepatitis C virus (HCV) infection typically relies upon blood samples taken ...
BACKGROUND We evaluated the field performance of a rapid point-of-care (POC) test for hepatitis B...
Background Efficient viral load testing is needed for hepatitis C (HCV) surveillance and diagnosis. ...
INTRODUCTION: Hepatitis C virus (HCV) antibody seroprevalence studies overestimate the true infectio...
Despite the widespread availability of curative treatment with direct-acting antivirals, a significa...
Eliminating hepatitis C as a public health threat requires an improved understanding of how to incre...
Background. Hepatitis C is one of the most prevalent blood-borne diseases in the United States. Desp...
Eliminating hepatitis C as a public health threat requires an improved understanding of how to incre...
BACKGROUND:Data on the true prevalence of hepatitis C virus (HCV) infection in the general populatio...
In New Zealand, approximately 50,000 people or more are infected with hepatitis C(HCV), and only 50%...
International audienceBackground: Although novel hepatitis C virus (HCV) RNA point‐of‐care technolog...
The relative contribution of serologic screening and nucleic acid testing (NAT) to prevent hepatitis...
Background Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage over antibody testi...
International audienceIntroduction: A lack of access to hepatitis C virus (HCV) diagnostics is a sig...
Background: Rapid tests for the detection of antibodies to hepatitis C virus (anti-HCV) can facilita...
Background: Testing for hepatitis C virus (HCV) infection typically relies upon blood samples taken ...
BACKGROUND We evaluated the field performance of a rapid point-of-care (POC) test for hepatitis B...
Background Efficient viral load testing is needed for hepatitis C (HCV) surveillance and diagnosis. ...
INTRODUCTION: Hepatitis C virus (HCV) antibody seroprevalence studies overestimate the true infectio...
Despite the widespread availability of curative treatment with direct-acting antivirals, a significa...
Eliminating hepatitis C as a public health threat requires an improved understanding of how to incre...
Background. Hepatitis C is one of the most prevalent blood-borne diseases in the United States. Desp...
Eliminating hepatitis C as a public health threat requires an improved understanding of how to incre...
BACKGROUND:Data on the true prevalence of hepatitis C virus (HCV) infection in the general populatio...
In New Zealand, approximately 50,000 people or more are infected with hepatitis C(HCV), and only 50%...
International audienceBackground: Although novel hepatitis C virus (HCV) RNA point‐of‐care technolog...
The relative contribution of serologic screening and nucleic acid testing (NAT) to prevent hepatitis...
Background Point-of-care hepatitis C virus (HCV) RNA testing offers an advantage over antibody testi...